[Edaily Reporter Kim Seung-kwon ] On the 16th, the domestic pharmaceutical and biotech sector saw a stark divergence in stock performance depending on clinical developments.
CORESTEMCHEMON(166480), which clarified the U.S. approval pathway for its ALS treatment, hit the daily price limit. #ARIBIOLAB also surged by more than 27% ahead of the announcement of the results from the global Phase 3 clinical trial of an oral Alzheimer’s disease treatment developed by its affiliate. In contrast, HLB Therapeutics(115450)plummeted to the daily price limit following news of the failure of its U.S. Phase 3 clinical trial for a treatment for neurotrophic keratitis.
Now, the market’s attention is focused on the Phase 3 results for AriBio’s “AR1001,” which are set to be released as early as the early morning of the 17th (Korea Standard Time).
ARIBIOLAB Rises 27% Ahead of AR1001 Phase 3 “D-Day”
According to KG Zeroin MP Doctor (formerly Marketpoint), ARIBIOLAB closed at 5,810 won today, up 1,240 won (27.13%) from the previous trading day. Compared to its low point at the end of July (1,824 won), the stock has more than tripled in just four months. Trading volume also surged to its highest level in recent months.
The stock price surge was driven by “AR1001” (active ingredient: mirodenafil), an Alzheimer’s disease treatment developed by affiliate AriBio. AriBio will present the results of its global Phase 3 clinical trial (POLARIS-AD) during the first oral presentation session at the Clinical Trials in Alzheimer’s Disease (CTAD 2026) conference, which opens in Boston, U.S., on the 16th (local time). This is expected to take place around early morning on the 17th (Korean time).
An AriBio official stated, “Today’s stock price rise appears to reflect anticipation of tomorrow morning’s AR1001 topline announcement,” adding, “While our employees have high expectations, the results remain a complete mystery even to us.”
POLARIS-AD is a large-scale clinical trial that enrolled 1,535 patients across approximately 230 institutions in 13 countries. Of these, 1,348 completed the 52-week trial. The results will be presented by Professor Sharon Sha of Stanford University School of Medicine, the global principal investigator (PI). These results will determine whether AriBio submits a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA).
AR1001 is a PDE5 inhibitor that AriBio licensed from SKCHEMICALS in 2011. Eisai and Biogen’s “Lecembi” and Eli Lilly’s “Kysena” are antibody therapies focused on removing beta-amyloid. In contrast, AR1001 employs a multi-mechanism approach that includes improving cerebral blood flow, protecting neurons, and activating autophagy.
Its key differentiators are convenience and safety. Lecembi requires intravenous injections every two weeks, and Kysena every four weeks. AR1001, on the other hand, is an oral medication taken once daily. It also carries a lower risk of cerebral edema and microhemorrhages (ARIA), which are common side effects of antibody therapies.
The groundwork for commercialization has also been laid. In May, AriBio signed a global option and licensing agreement worth up to $4.7 billion (approximately 7 trillion won) with China’s Fosun Pharmaceutical. It has also signed licensing agreements with SamjinPharmaceutical (South Korea) and Arserra (Middle East, Latin America, etc.), an affiliate of the United Arab Emirates’ sovereign wealth fund. Recently, following the registration of a patent in Japan, the company received a notice of impending patent registration from the European Patent Office (EPO).
Since AriBio is a privately held company, its affiliates—ARIBIOLAB and AriBio Holdings—are directly considered beneficiary stocks on the stock market. Last September, AriBio decided to invest 15 billion won in a 18 billion won third-party private placement by ARIBIOLAB. Once the capital increase is finalized, AriBio will become the largest shareholder of ARIBIOLAB. On the same day, AriBio Holdings also rose more than 10% during trading, and SamjinPharmaceutical—AriBio’s second-largest shareholder, which holds the domestic marketing rights for AR1001—also showed strong gains.
The company stated in an announcement, “We have received the clinical trial results notification and are currently analyzing it,” adding, “We plan to make an additional disclosure regarding the clinical trial results following a presentation at an academic conference.”
CORESTEMCHEMON Hits Daily Price Limit After FDA Confirms ‘Phase 3b Confirmatory Clinical Trial’ Pathway
CORESTEMCHEMON(166480)The stock closed at 1,807 won, up 417 won (30.00%) from the previous trading day, hitting the daily price limit. Although it fell to 1,300 won early in the session—marking a new low—buying pressure surged after news broke that the company had received the FDA meeting minutes. The stock rose by 39% from its intraday low.
CORESTEMCHEMON announced today that it had received the official minutes of the FDA’s “Type C meeting” regarding its stem cell therapy for Lou Gehrig’s disease (amyotrophic lateral sclerosis, ALS), “NeuronaTa-Alju” (active ingredient: Renjumestrocell). According to the minutes, the FDA agreed to the plan to evaluate the efficacy signals confirmed in previous clinical trials through a new confirmatory Phase 3b trial. The Phase 3b trial will be conducted as a prospective, randomized, double-blind, placebo-controlled study.
This is seen as a sign that the U.S. approval roadmap has become more concrete. Rather than applying for approval based solely on existing data, the company plans to first demonstrate efficacy in the Phase 3b trial and then submit a Biologics License Application (BLA).
There were also no major disagreements with the FDA regarding the clinical trial design. CORESTEMCHEMON proposed the change in the total score on the ALS Functional Rating Scale-Revised (ALSFRS-R) at Week 24 compared to baseline as the primary efficacy endpoint. The FDA raised no significant objections regarding the endpoint, inclusion criteria, or exclusion criteria. The agency also agreed to continue exploring the relationship between neurofilament light chain (NfL)—a biomarker of nerve damage—and clinical outcomes.
The safety assessment was positive. The FDA evaluated safety favorably based on completed Phase 2 and 3 trials and real-world data (RWD). It also agreed to the plan to combine Phase 3b safety data with existing data for submission in the BLA.
The possibility of utilizing domestic clinical data has also opened up. The FDA stated that it is open to accepting clinical results conducted in Korea, provided they meet the guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). CORESTEMCHEMON plans to conduct the Phase 3b trial in Korea, as it did with the preceding Phase 3 trial, and to pursue simultaneous approval from Korean and U.S. regulatory agencies.
The remaining challenge is manufacturing and quality control (CMC). The FDA stated that it has no objections to using vascular endothelial growth factor (VEGF) as the primary potency assay. However, comparative equivalence studies resulting from changes to the suspension formulation, shelf life, and manufacturing site will be discussed further at a “second Type C meeting.”
Neurona-R is a therapy made from mesenchymal stem cells extracted from the patient’s own bone marrow. It received conditional approval in Korea in 2014 and has been prescribed for over 10 years. Although the Phase 3 trial, which concluded in 2024, did not demonstrate statistical significance for the primary endpoint in the overall patient population, it confirmed improvements in efficacy indicators and NfL levels in the “slow-progressing” patient group, whose disease progresses relatively slowly. Last May, the company received approval from the Ministry of Food and Drug Safety (MFDS) for a marketing authorization amendment reflecting the Phase 3 data.
Yang Gil-an, CEO of CORESTEMCHEMON, stated, “Receiving the minutes from the FDA meeting has clarified the direction of the U.S. approval pathway toward a confirmatory Phase 3b clinical trial,” adding, “We will finalize the clinical trial design in subsequent meetings and prepare additional CMC data without delay.”
HLB Therapeutics Hits Daily Lower Limit Following Failure of U.S. Phase 3 Trial for RGN-259
HLB Therapeutics(115450)closed at 1,635 won, down 700 won (29.98%) from the previous trading day. The stock remained at the daily price limit from the opening to the closing bell.
HLB Therapeutics announced today that its U.S. subsidiary, Regentree, failed to achieve statistical significance for the primary endpoint in the U.S. Phase 3 clinical trial (SEER-2) of “RGN-259,” a candidate drug for neurotrophic keratitis (NK). The company received the top-line results from the contract research organization (CRO) on the 13th. No statistically significant difference was observed between the treatment group and the placebo group in the primary endpoint—the cure rate four weeks after administration.
RGN-259 is an eye drop candidate whose main ingredient is thymosin beta-4, a protein that promotes regeneration. Its mechanism of action involves promoting corneal wound healing and nerve regeneration. Neurotrophic keratitis is a rare degenerative eye disease in which damage to the corneal nerves leads to impaired sensation and a reduced ability for natural healing.
The drug has been evaluated as having sufficient market potential. Currently, Dompe’s “Oxevate” is virtually the only approved NK therapy. Oxevate must be refrigerated for 8 weeks and administered six times a day. RGN-259 can be stored at room temperature and administered five times a day for four weeks, so it was expected to offer superior convenience.
What makes this particularly painful is that it marks the second failure. Previously, in the European Phase 3 trial (SEER-3), the cure rate in the placebo group was higher than expected, resulting in a failure to achieve statistical significance. The company concluded that a lack of disease awareness and diagnostic experience among European healthcare providers led to inconsistencies in patient selection and evaluation. Subsequently, in the SEER-2 trial, the company overhauled its patient selection and evaluation procedures. Although the trial was expanded to a total of 50 centers—41 in the U.S. and 9 across three European countries—it failed to reverse the outcome.
The company plans to receive the full dataset within the next few weeks and conduct a comprehensive analysis of the detailed results for the primary endpoint, as well as the secondary endpoints and treatment responses across subgroups of patients.
Ahn Ki-hong, CEO of HLB Therapeutics, stated, “We plan to thoroughly analyze the complete clinical data to comprehensively verify the detailed results related to treatment efficacy,” adding, “Based on the analysis results, we will carefully review future development directions and plans.”
Korea Ratings (KRI) took the top spot in the “Credit Rating Reliability” category of the 37th Edaily Survey of Credit Rating Experts (SRE), maintaining its number one position for the fifth consecutiv…
CJ CheilJedang Corp. is taking steps to create a sustainable and safe sports environment by utilizing the biodegradable biomaterial “PHA” (polyhydroxyalkanoates). The company plans to introduce PHA-ba…
Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news. Corestem ChemOn hit the daily upper limit after clarifying its U.S. app…